Quick View
| Metric | Current Period | Same Period Last Year | YoY |
|---|---|---|---|
| Revenue | ¥2736.1B | ¥2636.6B | +3.8% |
| Operating Income | ¥14.0B | ¥16.0B | −12.2% |
| Ordinary Income | ¥23.7B | ¥25.3B | −6.5% |
| Net Income | ¥15.0B | ¥17.1B | −12.0% |
| ROE | 4.5% | 5.5% | - |
Executive Summary
The Company posted a mixed result of higher revenue but lower operating income and net income, highlighting weak cost absorption capacity under a low gross-margin structure. Revenue increased to ¥2,736.1B (+3.8% YoY), while operating income was ¥14.0B (-12.2%), ordinary income was ¥23.7B (-6.5%), and net income was ¥15.0B (¥17.1B in the prior year). SG&A expenses were burdensome at 4.6% of revenue versus a gross margin of 5.1%, and the thin operating-level profitability was the primary cause of the earnings decline.
Factors Affecting Performance
【Revenue】Revenue increased 3.8% YoY to ¥2,736.1B, representing progress of 75.2% against the earnings forecast of +4.2% YoY, broadly in line with standard progress.
【Profit and Loss】Operating income was ¥14.0B (-12.2% YoY). Under the low gross-margin structure in which cost of sales of ¥2,596.5B accounted for 94.9% of revenue, SG&A expenses of ¥125.6B (+6.4% YoY) absorbed approximately 90.0% of gross profit of ¥139.6B. Ordinary income of ¥23.7B exceeded operating income, supplemented by non-operating income of ¥11.3B, including ¥1.8B in dividend income. Non-operating income was equivalent to approximately 81% of operating income. Extraordinary losses of ¥0.8B, including losses on disposal of fixed assets, reduced profit before tax as a temporary factor. Net income was ¥15.0B (¥17.1B in the prior year), resulting in higher revenue but lower earnings, as revenue growth did not translate into profit growth.
Key Financial Metrics
【Profitability】The operating margin and net profit margin were both low at 0.5%, while the heavy SG&A burden relative to the 5.1% gross margin represents a structural constraint.【Cash Flow Quality】Comprehensive income was ¥25.8B, exceeding net income of ¥15.0B. However, the increase was primarily attributable to other comprehensive income, including ¥10.8B in valuation differences on securities, and should be assessed separately from recurring cash-generation capacity.【Investment Efficiency】ROE was 4.5%. A DuPont decomposition into a 0.6% net profit margin, 1.68x total asset turnover, and 4.90x financial leverage indicates that high leverage is supporting ROE.【Financial Soundness】The equity ratio declined to 20.4% from 22.2% in the prior year. Current liabilities of ¥1,233.3B account for the majority of total liabilities, making the turnover of short-term funding an important consideration.
Cash Flow Analysis
As cash flow statement figures have not been disclosed, funding trends are analyzed based on changes in the balance sheet. Cash and deposits increased to ¥57.7B from ¥28.8B in the prior year, while accounts receivable expanded to ¥852.2B (¥724.7B in the prior year) and inventories to ¥357.3B (¥288.0B in the prior year), indicating an increase in working capital associated with business expansion. Accounts payable also increased to ¥774.0B (¥580.2B in the prior year), absorbing part of working capital through the use of trade payables. Annualized DSO for accounts receivable was approximately 85 days, and the fact that revenue growth was accompanied by increased funding requirements is a point to monitor from a capital-efficiency perspective.
Earnings Quality
Of ordinary income of ¥23.7B, operating income accounted for only ¥14.0B, with the remainder substantially supplemented by non-operating income of ¥11.3B, including ¥1.8B in dividend income and ¥3.0B in other non-operating income. Accordingly, the sustainability of ordinary income also depends on the sustainability of non-operating income. Extraordinary items comprised extraordinary gains of ¥0.2B and extraordinary losses of ¥0.8B, acting as a temporary factor that reduced profit before tax by ¥0.5B on a net basis. Comprehensive income of ¥25.8B exceeded net income of ¥15.0B, but the primary source of the difference was other comprehensive income, including valuation differences on securities, which does not represent cash-generation capacity from business activities. Overall, earnings quality requires monitoring because operating-level profitability is thin and the factors boosting ordinary and comprehensive income depend on non-business items.
Earnings Forecast and Guidance
The full-year forecast calls for revenue of ¥3,640.0B (+4.2% YoY), operating income of ¥30.9B (+11.8%), and ordinary income of ¥43.7B (+9.5%). While progress through Q3 was 75.2% for revenue, close to standard progress, progress for operating income, ordinary income, and net income was 45.3%, 54.2%, and 49.5%, respectively, all below the standard progress rate of 75%. Achieving the full-year operating income forecast will require approximately ¥16.9B in operating income in Q4 alone, a significant improvement over the average quarterly operating income of ¥4.7B through Q3. The lag in profit progress relative to revenue progress will be a key point in assessing the likelihood of achieving the full-year forecast.
Shareholder Returns
The full-year dividend forecast is ¥28 per share, an increase from ¥26 per share in the prior year. The forecast payout ratio is approximately 12.5%, calculated by dividing the total dividend amount based on the forecast dividend of ¥28 and the average number of shares outstanding during the period of 1,364.1万 shares by forecast net income of ¥30.6B. The dividend burden is therefore low relative to the earnings level. As operating cash flow has not been disclosed, cash-based dividend coverage cannot be assessed; however, dividend capacity is relatively high on an earnings basis.
Risk Factors
-
Profitability risk from the low gross-margin structure: SG&A expenses are burdensome at 4.6% of revenue versus a gross margin of 5.1%. If increases in procurement prices, logistics costs, and personnel expenses cannot be passed on through pricing, operating income (currently ¥14.0B, with a 0.5% margin) could come under further pressure.
-
Financial leverage and refinancing risk: The equity ratio declined to 20.4% from 22.2% in the prior year, while current liabilities account for more than 95% of total liabilities. Short-term liabilities, including short-term borrowings of ¥96.9B, are large relative to cash and deposits of ¥57.7B, resulting in high sensitivity to refinancing conditions and the interest-rate environment.
-
Gap between revenue progress and profit progress: Progress against the full-year forecast was substantially lower for operating income at 45.3% and net income at 49.5% than for revenue at 75.2%. Unless profit improves rapidly in Q4, the likelihood of achieving the full-year forecast will decline.
Industry Benchmark (For Reference; Based on the Company's Research)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 0.5% | 3.3% (1.8%–5.0%) | −2.8pt |
| Net Profit Margin | 0.5% | 3.1% (1.4%–6.3%) | −2.6pt |
Profitability was substantially below the industry median, with both the operating margin and net profit margin ranking toward the lower end of the industry.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 3.8% | 5.2% (-4.1%–8.6%) | −1.4pt |
The revenue growth rate was slightly below the industry median but remained within the IQR range.
※Source: Based on the Company's research
Key Points from the Financial Results
-
Revenue increased 3.8% YoY and was broadly tracking at a standard pace against the full-year forecast, while operating income decreased 12.2% YoY, confirming a results structure characterized by simultaneous revenue growth and earnings decline.
-
Under the low-profitability structure represented by a 0.5% operating margin and a 5.1% gross margin, SG&A expenses absorbed approximately 90% of gross profit, while ordinary income depended to a certain extent on supplementation from non-operating income, including dividend income.
-
Although the dividend forecast was increased to ¥28 per share from ¥26 per share in the prior year, progress toward the full-year earnings forecast remained at 49.5% for net income, leaving dividend sustainability dependent on the extent of profit improvement in the second half of the fiscal year.
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with a professional as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
FY2026 Q3 results were operationally soft despite continued top-line growth, with the profit shortfall versus full-year guidance now the principal issue. Cumulative revenue increased 3.8% YoY to ¥273.61bn. Gross profit rose 4.2% to ¥13.96bn, marginally outpacing sales growth. The gross margin improved by approximately 2bp YoY to 5.1%. However, SG&A expenses increased 6.4% YoY to ¥12.56bn, faster than revenue growth. Consequently, operating income declined 12.2% to ¥1.40bn. The operating margin contracted by approximately 9bp YoY to 0.5%. Ordinary income decreased 6.5% to ¥2.37bn, with net non-operating income of ¥0.97bn materially cushioning the weak operating result. Net income attributable to owners declined 12.0% to ¥1.51bn, and the net margin narrowed by roughly 10bp to 0.6%. Dividend income of ¥0.18bn contributed to non-operating income, while other non-operating income was also significant. Extraordinary losses of ¥0.08bn exceeded extraordinary gains of ¥0.02bn, though the absolute effect on earnings was limited. The annualized ROE was 6.1%, below the stated 8% concern benchmark and supported more by high financial leverage than by margin strength. Balance-sheet expansion was concentrated in receivables, inventories and cash, while trade payables also increased substantially. The current ratio was 112.0%, avoiding an immediate liquidity warning, but the 83.1% quick ratio indicates meaningful dependence on inventory conversion and receivables collection. Q3 revenue progress reached 75.2% of full-year guidance, broadly aligned with the standard 75% seasonal benchmark. In contrast, operating-income progress was only 45.3%, ordinary-income progress 54.2%, and attributable-profit progress 49.5%, requiring a substantial Q4 earnings recovery to achieve company guidance. The earnings outlook therefore depends on restoring operating margin, containing SG&A growth and converting the enlarged working-capital base efficiently.
Profitability Analysis
The annualized DuPont ROE is 6.1%, comprising a 0.6% net profit margin, 2.240x asset turnover and 4.90x financial leverage. The low net margin is the dominant constraint on shareholder returns, while leverage rather than operating profitability is the principal support for ROE. Revenue grew 3.8% YoY, but operating income fell 12.2%, demonstrating negative operating leverage as SG&A growth of 6.4% exceeded sales growth. Gross margin improved modestly to 5.1% from approximately 5.08% in the prior-year period, indicating that gross-profit generation was not the main source of the operating-income decline. Instead, SG&A as a percentage of sales rose to approximately 4.59% from 4.48%, an increase of about 11bp. This caused operating margin to fall to 0.51% from approximately 0.61%, or about 9bp of compression. Net margin similarly declined to approximately 0.55% from 0.65%, or roughly 10bp. Ordinary income was more resilient than operating income because net non-operating income amounted to ¥0.97bn, equivalent to around 69% of operating income. Dividend income of ¥0.18bn was a recurring-looking contributor, although the scale of other non-operating income makes operating income the cleaner indicator of underlying earnings momentum. The effective tax rate was 35.2%, producing a tax burden of 0.655 and modestly reducing conversion from pre-tax profit to net income. The reported interest coverage ratio of 14.02x remains adequate, but interest expense increased to ¥0.10bn from ¥0.04bn in the prior-year period. The quality alert for low operating efficiency is justified: a 0.5% EBIT margin leaves limited room to absorb procurement, logistics, labor or pricing pressures. The annualized ROIC alert of 3.2% also indicates that capital employed is generating returns below the stated 5% warning threshold. Sustainable profitability improvement will require SG&A discipline and margin preservation rather than further balance-sheet expansion alone.
Growth Assessment
Sales growth of 3.8% YoY to ¥273.61bn demonstrates continued volume or distribution growth in the healthcare wholesale business. Gross profit increased 4.2%, slightly faster than sales, supporting the modest improvement in gross margin. However, the decline in operating profit and net profit indicates that current growth is not translating proportionately into earnings. The company forecasts full-year revenue growth of 4.2% to ¥364.00bn, and Q3 revenue progress of 75.2% is broadly consistent with achieving that target. Full-year operating income guidance is ¥3.09bn, implying Q4 operating income of ¥1.69bn. That required Q4 operating income exceeds the cumulative Q1-Q3 operating income of ¥1.40bn, highlighting a demanding profit recovery requirement. Full-year ordinary-income guidance of ¥4.37bn requires ¥2.00bn in Q4, while attributable-profit guidance of ¥3.06bn requires ¥1.54bn in Q4. Accordingly, earnings progress is 29.7 percentage points below the standard 75% benchmark for operating income, 20.8 points below for ordinary income, and 25.5 points below for attributable profit. The implied recovery must come from a combination of seasonal sales, improved cost absorption, tighter SG&A control and continued non-operating contributions. Given the thin 5.1% gross margin, even modest changes in supplier terms, product mix or distribution costs can materially affect operating profit. The growth profile is therefore revenue-positive but profit-conversion constrained.
Financial Health
Liquidity is adequate but relatively tight for a working-capital-intensive distributor. The current ratio is 112.0%, above 1.0x, and working capital is ¥14.84bn. However, the quick ratio is 83.1%, below 1.0x, showing that liquidity depends partly on inventory realization and receivables collection. Current assets represented 84.8% of total assets, including receivables of ¥85.22bn and inventories of ¥35.73bn. Receivables alone accounted for 52.3% of total assets, and the 85-day DSO quality alert points to elevated collection-cycle exposure. Total liabilities represented 79.6% of total assets, leaving an equity ratio of 20.4%. D/E is 3.90x, well above the 2.0x warning threshold, and explicitly signals aggressive balance-sheet leverage when measured against total equity. Interest-bearing debt was ¥10.56bn, equal to 24.1% of capital, which is less severe than the total-liability D/E ratio suggests. Interest coverage of 14.02x remains solid, reducing immediate debt-service pressure. Refinancing risk is nevertheless material because 91.8% of interest-bearing debt is short term. Short-term loans totaled ¥9.69bn, while cash and deposits were ¥5.77bn, resulting in cash coverage of only 0.60x of short-term debt. This maturity structure requires dependable access to bank funding and continued turnover of trade receivables and inventories. Accounts payable increased ¥19.38bn YoY to ¥77.40bn, partly financing the expansion in receivables and inventory. Electronically recorded operating obligations also increased to ¥26.68bn from ¥23.69bn. The increase in trade-credit funding supports operating liquidity but raises sensitivity to supplier payment terms and funding-market conditions. Investment securities of ¥13.31bn, or 8.2% of total assets, and valuation-related equity reserves provide some balance-sheet value support, but do not substitute for operating cash liquidity.
Notable B/S Changes
Cash and deposits: +¥2.89bn (+100.3%) to ¥5.77bn - improves nominal liquidity, although cash covers only 0.60x of short-term debt. Accounts receivable: +¥12.75bn (+17.6%) to ¥85.22bn - a major use of balance-sheet capacity; elevated 85-day DSO increases collection and funding risk. Inventories: +¥6.93bn (+24.1%) to ¥35.73bn - expansion is material in absolute terms and increases dependence on inventory turnover in a low-margin distribution model. Accounts payable: +¥19.38bn (+33.4%) to ¥77.40bn - supplier credit materially funded working-capital growth, but increases sensitivity to payment terms and trade-finance availability. Total assets: +¥23.55bn (+16.9%) to ¥162.89bn - asset growth exceeded sales growth and was concentrated in working-capital accounts, limiting capital-efficiency improvement. Total equity: +¥2.22bn (+7.2%) to ¥33.28bn - equity grew more slowly than assets and liabilities, contributing to the elevated 3.90x D/E ratio.
Cash Flow Quality
Dividend Sustainability
The full-year forecast dividend is ¥28 per share, compared with ¥26 per share in the prior period. Using forecast attributable profit of ¥3.06bn and the reported average share count of 13.64 million, implied forecast EPS is approximately ¥224.2. The implied dividend payout ratio is therefore approximately 12.5%, which is conservative on an earnings basis. This low payout leaves a substantial accounting earnings buffer even if the company falls short of its full-year profit target. Dividend capacity should nevertheless be assessed alongside the company’s working-capital funding needs, given the high receivable balance, low quick ratio and predominance of short-term debt. The modest dividend commitment appears less demanding than preserving liquidity and maintaining bank funding capacity.
Risk Assessment
Business risks include Margin risk: The 5.1% gross margin and 0.5% operating margin leave earnings highly sensitive to supplier pricing, rebates, logistics costs, labor costs and product mix. The low gross-margin quality alert is structurally relevant for a healthcare distribution business, where price competition and regulated reimbursement dynamics can limit pass-through., Execution risk versus guidance: Operating-income progress is 45.3% against a standard Q3 benchmark of 75%, requiring Q4 operating income of ¥1.69bn to meet full-year guidance., Receivables and inventory risk: Receivables of ¥85.22bn and inventory of ¥35.73bn dominate the asset base. The 85-day DSO alert raises exposure to slower collections, customer credit deterioration and working-capital absorption., Healthcare industry risk: Changes in drug pricing, reimbursement policy, customer purchasing concentration and competition among pharmaceutical and healthcare-product distributors may compress already thin distribution margins..
Financial risks include High leverage: D/E of 3.90x exceeds the 2.0x warning threshold. While interest-bearing debt is more moderate at 24.1% of capital, the overall liability-heavy capital structure limits resilience to earnings volatility., Refinancing risk: The short-term debt ratio is 91.8%, with ¥9.69bn of short-term loans and cash covering only 0.60x of that amount. Continued lender support and working-capital turnover are important., Low capital efficiency: Annualized ROIC of 3.2% is below the 5% warning threshold, suggesting returns may not adequately compensate for the capital tied up in the distribution platform., Interest-cost sensitivity: Interest expense rose to ¥0.10bn from ¥0.04bn YoY. Coverage remains sound at 14.02x, but further rate increases would reduce earnings in a low-margin model..
Key concerns include SG&A grew 6.4% YoY against 3.8% sales growth, resulting in a 12.2% decline in operating income., Non-operating income materially supported ordinary income, making operating income the key measure to monitor for underlying earnings recovery., Trade payables rose 33.4% YoY, indicating heavier use of supplier financing alongside the expansion of receivables and inventories., High leverage, short-term funding reliance, elevated DSO and low ROIC combine to create a balance sheet that is sensitive to any deterioration in working-capital efficiency..
Investment Implications
Key takeaways include Revenue is tracking full-year guidance, but profit progress is materially behind plan., A small gross-margin improvement was outweighed by SG&A deleverage, driving operating-margin compression., Annualized ROE of 6.1% is below the 8% concern benchmark and is supported by 4.90x financial leverage rather than strong net margins., The ¥28 forecast dividend implies a conservative approximately 12.5% payout ratio based on forecast earnings., The operating model requires close monitoring of receivable collection, inventory turnover and supplier-credit funding..
Metrics to watch include Q4 operating income versus the ¥1.69bn implied requirement to meet full-year guidance, Operating margin and SG&A-to-sales ratio, DSO, receivables balance and inventory growth, Short-term loan balance, cash-to-short-term-debt coverage and refinancing terms, Interest expense and interest coverage, Annualized ROIC and ROE.
Regarding relative positioning, The company exhibits the characteristics of a low-margin healthcare distributor: high asset turnover and supplier-financed working capital can support returns, but profitability is vulnerable to modest cost or pricing movements. Its annualized ROE of 6.1% and ROIC of 3.2% indicate weaker capital efficiency than the stated return benchmarks, while its 3.90x D/E ratio and 91.8% short-term debt ratio imply a more aggressive funding profile than a conservatively capitalized peer.